Lecap Asset Management Ltd. Takes Position in Insulet Corporation $PODD

Key Points

• Lecap Asset Management Ltd. purchased 1,678 shares of Insulet Corporation, valued at approximately $527,000, indicating institutional confidence in the medical instruments supplier.
• Analysts have raised their price targets for Insulet, with JPMorgan Chase increasing theirs from $340.00 to $415.00, highlighting a positive outlook for the company's stock.
• Insulet reported an EPS of $1.17 for the last quarter, beating the consensus estimate of $0.92, and saw a revenue increase of 32.9% year-over-year.

Lecap Asset Management Ltd. bought a new position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,678 shares of the medical instruments supplier's stock, valued at approximately $527,000.

Several other institutional investors also recently bought and sold shares of PODD. ASR Vermogensbeheer N.V. boosted its holdings in shares of Insulet by 27.0% during the 2nd quarter. ASR Vermogensbeheer N.V. now owns 4,158 shares of the medical instruments supplier's stock valued at $1,306,000 after purchasing an additional 884 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its position in shares of Insulet by 141.4% in the second quarter. Robeco Institutional Asset Management B.V. now owns 204,494 shares of the medical instruments supplier's stock worth $64,248,000 after buying an additional 119,786 shares in the last quarter. LBP AM SA bought a new position in Insulet during the second quarter valued at approximately $4,910,000. Arcadia Wealth Management LLC purchased a new position in Insulet during the 2nd quarter valued at approximately $207,000. Finally, Chicago Capital LLC grew its holdings in Insulet by 3.9% during the 2nd quarter. Chicago Capital LLC now owns 177,996 shares of the medical instruments supplier's stock valued at $55,923,000 after buying an additional 6,702 shares in the last quarter.

Analysts Set New Price Targets

Several analysts have recently issued reports on PODD shares. JPMorgan Chase & Co. increased their target price on Insulet from $340.00 to $415.00 and gave the company an "overweight" rating in a research report on Friday, September 12th. Oppenheimer increased their price objective on shares of Insulet from $324.00 to $365.00 and gave the company an "outperform" rating in a research report on Monday, September 8th. Royal Bank Of Canada boosted their target price on shares of Insulet from $330.00 to $350.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Wall Street Zen raised shares of Insulet from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Morgan Stanley reiterated an "overweight" rating on shares of Insulet in a research report on Thursday, August 7th. Sixteen investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, Insulet currently has a consensus rating of "Moderate Buy" and a consensus price target of $345.47.

Insulet Trading Up 2.0%

Shares of NASDAQ PODD opened at $312.21 on Friday. Insulet Corporation has a fifty-two week low of $225.37 and a fifty-two week high of $353.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The company has a market cap of $21.98 billion, a price-to-earnings ratio of 94.90, a PEG ratio of 2.54 and a beta of 1.40. The business's 50 day moving average price is $320.96 and its 200-day moving average price is $298.20.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. During the same quarter in the prior year, the company posted $0.55 EPS. Insulet's quarterly revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, sell-side analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Activity

In other news, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Laetitia Cousin sold 797 shares of the business's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares of the company's stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.